[en] The <<Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction>> (PARAGON HF) trial is a multicenter, randomized, double-blind study comparing the incidence of heart failure hospitalization and cardiovascular mortality in patients with heart failure with preserved ejection fraction (HFpEF) treated with sacubitril/valsartan (Entresto(R)) versus valsartan alone. After a median follow-up of 35 months, the primary endpoint was reduced by 13 % in the sacubitril/valsartan group compared to the valsartan group (relative risk: 0.87, 95 % IC: 0.753-1.005, p = 0.058). Despite this lack of significance, the incidence of hospitalizations for heart failure was reduced (RR 0.85, 95 % CI: 0.72-1.00), whereas no benefit was observed on cardiovascular mortality. A subgroup analysis suggested that women and patients with an intermediate ejection fraction could get more benefit from the treatment. Concerning secondary criteria, a significant improvement in quality of life and in heart failure symptoms was observed in the group sacubitril/valsartan. There was a greater incidence of arterial hypotension and angioneurotic edema, but a lower incidence of hyperkalemia in the group sacubitril/valsartan.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
TRIDETTI, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie
NGUYEN TRUNG, Mai-Linh ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie
ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Insuffisance cardiaque - Transplantation
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Language :
French
Title :
L'etude clinique du mois. PARAGON-HF : sacubitril/valsartan (Entresto(R)) dans l'insuffisance cardiaque a fraction d'ejection preservee (HFpEF).
Alternative titles :
[en] The PARAGON-HF trial
Publication date :
2020
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium